Synthetic Biologics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SYN and buy or sell other stocks, ETFs, and their options commission-free!

About SYN

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. 

CEO
Steven A. Shallcross, MBA, CPA
CEOSteven A. Shallcross, MBA, CPA
Employees
22
Employees22
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2001
Founded2001
Employees
22
Employees22

SYN Key Statistics

Market cap
1.37M
Market cap1.37M
Price-Earnings ratio
-0.03
Price-Earnings ratio-0.03
Dividend yield
Dividend yield
Average volume
5.27M
Average volume5.27M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$10.75
52 Week high$10.75
52 Week low
$0.47
52 Week low$0.47

Stock Snapshot

The current Synthetic Biologics(SYN) stock price is $0.49, with a market capitalization of 1.37M. The stock trades at a price-to-earnings (P/E) ratio of -0.03.

On 2026-03-14, Synthetic Biologics(SYN) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 5.27M.

The stock's 52-week range extends from a low of $0.47 to a high of $10.75.

The stock's 52-week range extends from a low of $0.47 to a high of $10.75.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.